AGENUS INC
About AGENUS INC
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $114.2M
- Net income
- -$120.7M
- Total assets
- $226.8M
- Market cap
- $134.5M
- Gross margin
- 99.1%
- Operating margin
- -17.7%
- Net margin
- -2.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $114.2M
- Cost of revenue
- $1.0M
- Gross profit
- $113.2M
- Operating expenses
- $133.3M
- Operating income
- -$20.2M
- Income tax
- $0
- Net income
- -$3.1M
- EPS (basic)
- $0.00
- EPS (diluted)
- $0.00
Balance sheet
- Total assets
- $226.8M
- Current assets
- $133.4M
- Total liabilities
- $504.7M
- Current liabilities
- $323.5M
- Shareholders’ equity
- -$277.9M
Cash flow
- Operating cash flow
- -$77.2M
- Investing cash flow
- $1.2M
- Financing cash flow
- $36.6M
- Net cash flow
- -$39.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $134.5M
- Shares outstanding
- 43.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 4, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $120.7M in FY2025.
- Revenue declined 61% from FY2021 to FY2025.
- Gross margin of 99.1%, net margin -2.7%.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AGENUS INC.
Write a review
News about AGENUS INC
News & sentiment via Polygon.io
